[1]
Hühmer A.F., Biringer R.G., Amato H., et al.: Protein Analysis in Human
Cerebrospinal Fluid: Physiological Aspects, Current Progress and Future
Challenges. Dis Markers 2006; 22: 3–26.
[2]
Petry F., Torzewski M., Bohl J., et al.: Early Diagnosis of Acanthamoeba
Infection during Routine Cytological Examination of Cerebrospinal Fluid.
J Clin Microbiol 2006; 44: 1903–1904.
[3]
Pfisterer W.: Early diagnosis of external ventricular drainage infection:
results of a prospective study. J Neurol Neurosurg Psychiatry 2003; 74:
929–932.
[4]
Dougherty J.M., Jones J.: Cerebrospinal fluid cultures and analysis. Ann
Emerg Med 1986; 15: 317–323.
[5]
van de Beek D., de Gans J., Spanjaard L., et al.: Clinical Features and
Prognostic Factors in Adults with Bacterial Meningitis. N Engl J Med
2004; 351: 1849–1859.
[6]
Dalal I., Tzhori S., Somekh E., et al.: Cytokine profile in cerebrospinal fluid
of children with echovirus type 4 meningitis. Pediatr Neurol 2003; 29:
312–316.
[7]
Cepok S., Zhou D., Vogel F., et al.: The immune response at onset and
during recovery from Borrelia burgdorferi meningoradiculitis. Arch
Neurol 2003; 60: 849–855.
[8]
Cerar T., Ogrinc K., Lotrič-Furlan S., et al.: Diagnostic Value of Cytokines
and Chemokines in Lyme Neuroborreliosis. Clin Vaccine Immunol 2013;
20: 1578–8154.
[9]
Zheng Y., Humphry M., Maguire J.J., et al.: Intracellular interleukin-1
receptor 2 binding prevents cleavage and activity of interleukin-1α,
controlling necrosis-induced sterile inflammation. Immunity 2013; 38:
285–925.
[10]
Peters V.A., Joesting J.J., Freund G.G.: IL-1 receptor 2 (IL-1R2) and its role
in immune regulation. Brain Behav Immun 2013; 32: 1–8.
[11]
Goshen I., Yirmiya R.: Interleukin-1 (IL-1): a central regulator of stress
responses. Front Neuroendocrinol 2009; 30: 30–45.
[12]
Seppi D., Puthenparampil M., Federle L., et al.: Cerebrospinal fluid IL-
1βcorrelates with cortical pathology load in multiple sclerosis at clinical
onset. J Neuroimmunol 2014; 270: 56–60.
[13]
Ye L., Huang Y., Zhao L., et al.: IL-1β and TNF-α induce neurotoxicity
through glutamate production: a potential role for neuronal glutaminase.
J Neurochem 2013; 125: 897–908.
[14]
Song C., Zhang Y., Dong Y.: Acute and subacute IL-1β administrations
differentially modulate neuroimmune and neurotrophic systems:
possible implications for neuroprotection and neurodegeneration. J
Neuroinflammation 2013; 10: 826 [14 screen pages] Address:[15
screen pages] Address: https://jneuroinflammation.biomedcentral.com/
articles/10.1186/1742-2094-10-59#citeas.
[15]
Sulik A., Kroten A., Wojtkowska M., et al.: Increased Levels of Cytokines
in Cerebrospinal Fluid of Children with Aseptic Meningitis Caused by
Mumps Virus and Echovirus 30. Scand J Immunol 2014; 79: 68–72.
[16]
Rossi S., Furlan R., De Chiara V., et al.: Interleukin-1β causes synaptic
hyperexcitability in multiple sclerosis. Ann Neurol 2012; 71: 76–83.
[17]
Popescu B.F.G., Bunyan RF, Parisi JE, et al.: A case of multiple sclerosis
presenting with inflammatory cortical demyelination. Neurology 2011;
76: 1705–1710.
[18]
Maimone D., Gregory S., Arnason B.G., et al.: Cytokine levels in the
cerebrospinal fluid and serum of patients with multiple sclerosis. J
Neuroimmunol 1991; 32: 67–74.
[19]
Spulber S., Bartfai T., Schultzberg M.: IL-1/IL-1RA balance in the brain
revisited - evidence from transgenic mouse models. Brain Behav Immun
2009; 23: 573–579.
[20]
Griffin É.W., Skelly D.T., Murray C.L., et al.: Cyclooxygenase-1-dependent
prostaglandins mediate susceptibility to systemic inflammation-induced
acute cognitive dysfunction. J Neurosci Off J Soc Neurosci 2013; 33:
15248–15258.
[21]
Kwon A., Kwak B.O., Kim K., et al.: Cytokine levels in febrile seizure
patients: A systematic review and meta-analysis. Seizure 2018; 59:
5-10.
[22]
Kitazawa M., Cheng D., Tsukamoto M., et al.: Blocking Interleukin-1
Signaling Rescues Cognition, Attenuates Tau Pathology, and Restores
Neuronal β-Catenin Pathway Function in an Alzheimer’s Disease Model.
J Immunol Baltim Md 2011; 187: 6539–6549.
[23]
Oprica M., Hjorth E., Spulber S., et al.: Studies on brain volume, Alzheimer-
related proteins and cytokines in mice with chronic overexpression of
IL-1 receptor antagonist. J Cell Mol Med 2007; 11: 810–825.
[24]
Emsley H.C.A., Smith C.J., Georgiou R.F., et al.: A randomised phase
II study of interleukin-1 receptor antagonist in acute stroke patients. J
Neurol Neurosurg Psychiatry 2005; 76: 1366–1372.
[25]
Oygur N., Sonmez O., Saka O., et al.: Predictive value of plasma
and cerebrospinal fluid tumour necrosis factor-α and interleukin-
1βconcentrations on outcome of full term infants with hypoxic-ischaemic
encephalopathy. Arch Dis Child Fetal Neonatal Ed 1998; 79: F190–3.
[26]
Aly H., Khashaba M.T., El-Ayouty M., et al.: IL-1β, IL-6 and TNF-α and
outcomes of neonatal hypoxic ischemic encephalopathy. Brain Dev
2006; 28: 178–182.
[27]
. Boeer K., Vogelsang H., Deufel T., et al.: Immediate diagnosis of
ventriculits: evaluation of parameters independent of microbiological
culture. Acta Neurochir 2011; 153: 1797–1805.
[28]
McCracken G.H., Mustafa M.M., Ramilo O., et al.: Cerebrospinal fluid
interleukin 1-beta and tumor necrosis factor concentrations and outcome
from neonatal gram-negative enteric bacillary meningitis. Pediatr Infect
Dis J 1989; 8: 155–159.
[29]
Low P.S., Lee B.W., Yap H.K., et al.: Inflammatory response in bacterial
meningitis: cytokine levels in the cerebrospinal fluid. Ann Trop Paediatr
1995; 15: 55–59.
[30]
Vlachogiannis P., Hillered L., Khalil F., et al.: Interleukin-6 Levels in
Cerebrospinal Fluid and Plasma in Patients with Severe Spontaneous
Subarachnoid Hemorrhage. World Neurosurg 2019; 122: e612–8.
[31]
Moreno V.P., Subirá D., Meseguer E., et al.: IL-6 as a biomarker of ischemic
cerebrovascular disease. Biomark Med 2008;2:125–136.
[32]
Heinrich P.C., Castell J.V., Andus T.: Interleukin-6 and the acute phase
response. Biochem J 1990; 265: 621–636.
[33]
Prasad R., Kapoor R., Srivastava R., et al.: Cerebrospinal Fluid TNF-α,
IL-6, and IL-8 in Children With Bacterial Meningitis. Pediatr Neurol 2014;
50: 60–65.
[34]
Matsuzono Y., Narita M., Akutsu Y., et al.: Interleukin-6 in cerebrospinal
fluid of patients with central nervous system infections. Acta Paediatr
1995; 84: 879–883.
[35]
Pinto Junior V.L.L., Rebelo M.C., Gomes R.N., et al.: IL-6 and IL-8 in
cerebrospinal fluid from patients with aseptic meningitis and bacterial
meningitis: their potential role as a marker for differential diagnosis. Braz
J Infect Dis 2011; 15: 156–158.
[36]
Azuma H., Tsuda N., Sasaki K., et al.: Clinical significance of cytokine
measurement for detection of meningitis. J Pediatr 1997; 131: 463–465.
Corresponding author: Anna Mania, Klinika Chorób Zakaźnych i Neurologii Dziecięcej, ul. Szpitalna 27/33, 60-572 Poznań,
e-mail: amania@ump.edu.pl, tel. kom: 605034122
[37]
Buck C., Bundschu J., Gallati H., et al.: Interleukin-6: a sensitive parameter
for the early diagnosis of neonatal bacterial infection. Pediatrics 1994;
93: 54–58.
[38]
Hasegawa S., Matsushige T., Inoue H., et al.: Serum and cerebrospinal
fluid cytokine profile of patients with 2009 pandemic H1N1 influenza
virus-associated encephalopathy. Cytokine 2011; 54: 167–172.
[39]
Ichiyama T., Ito Y., Kubota M., et al.: Serum and cerebrospinal fluid
levels of cytokines in acute encephalopathy associated with human
herpesvirus-6 infection. Brain Dev 2009; 31: 731–738.
[40]
Winter P.M., Dung N.M., Loan H.T., et al.: Proinflammatory cytokines
and chemokines in humans with Japanese encephalitis. J Infect Dis. 1
listopad 2004; 190: 1618–1626.
[41]
Protas P., Holownia A., Muszynska-Roslan K., et al.: Cerebrospinal Fluid
IL-6, TNF-α and MCP-1 in children with acute lymphoblastic leukaemia
during chemotherapy. Neuropediatrics 2011; 42: 254–256.
[42]
Engler H., Brendt P., Wischermann J., et al.: Selective increase of
cerebrospinal fluid IL-6 during experimental systemic inflammation in
humans: association with depressive symptoms. Mol Psychiatry 2017;
22: 1448–5144.
[43]
. Kothur K., Troedson C., Webster R., et al.: Elevation of cerebrospinal
fluid cytokine/chemokines involved in innate, T cell, and granulocyte
inflammation in pediatric focal cerebral arteriopathy. Int J Stroke 2019;
14: 154–158.
[44]
Srinivasan L., Kilpatrick L., Shah S.S., et al.: Cerebrospinal fluid cytokines
in the diagnosis of bacterial meningitis in infants. Pediatr Res 2016; 80:
566–572.
[45]
Ichiyama T., Shoji H., Kato M., et al.: Cerebrospinal fluid levels of cytokines
and soluble tumour necrosis factor receptor in acute disseminated
encephalomyelitis. Eur J Pediatr 2002; 161: 133–137.
[46]
Koedel U., Bernatowicz A., Frei K., et al.: Systemically (but not
intrathecally) administered IL-10 attenuates pathophysiologic alterations
in experimental pneumococcal meningitis. J Immunol 1996; 157: 185–
191.
[47]
. Glimaker M., Kragsbjerg P., Forsgren M., et al.: Tumor Necrosis Factor-
(TNF ) in Cerebrospinal Fluid from Patients with Meningitis of Different
Etiologies: High Levels of TNF Indicate Bacterial Meningitis. J Infect Dis
1993; 167: 882–889.
[48]
Lopez-Cortes L.F., Cruz-Ruiz M., Gomez-Mateos J., et al.: Measurement
of Levels of Tumor Necrosis Factor- and Interleukin-1 in the CSF of
Patients with Meningitis of Different Etiologies: Utility in the Differential
Diagnosis. Clin Infect Dis 1993; 16: 534–539.
[49]
Taira N., Kamei S., Morita A., et al.: Predictors of a prolonged clinical
course in adult patients with herpes simplex virus encephalitis. Intern
Med Tokyo Jpn 2009; 48: 89–94.
[50]
Nakajima W., Ishida A., Lange M.S., et al.: Apoptosis Has a Prolonged
Role in the Neurodegeneration after Hypoxic Ischemia in the Newborn
Rat. J Neurosci 2000; 20: 7994–8004.
[51]
Abboud A., Mi Q., Puccio A., et al.: Inflammation Following Traumatic
Brain Injury in Humans: Insights from Data-Driven and Mechanistic
Models into Survival and Death. Front Pharmacol 2016 27; 7: 342.
[52]
. Matsuzono Y., Narita M., Akutsu Y., et. al.: Interleukin-6 in cerebrospinal
fluid of patients with central nervous system infections. Acta Paediatrica
1995; 84: 879–883.
[53]
Sato M., Hosoya M., Honzumi K., et al.: Cytokine and Cellular Inflammatory
Sequence in Enteroviral Meningitis. Pediatrics 2003; 112: 1103–1107.
[54]
Ye N., Gong X., Pang L., et al.: Cytokine responses and correlations
thereof with clinical profiles in children with enterovirus 71 infections.
BMC Infect Dis 2015: 225.
[55]
Perrella O., Sbreglia C., Perrella M., et al.: Interleukin-10 and tumor
necrosis factor-alpha: model of immunomodulation in multiple sclerosis.
Neurological Research 2006; 28: 193–195.
[56]
Niwa A., Osuka K., Nakura T., et al.: Interleukin-6, MCP-1, IP-10, and MIG
are sequentially expressed in cerebrospinal fluid after subarachnoid
hemorrhage. J Neuroinflammation 2016; 13: 217.
Scholar Google
PubMed